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Abstract
Background: The concept of tissue engineering is to deliver to the injury site biological scaffolds carrying functional
cells that will enhance healing response. The preferred cell source is autologous in order to reduce immune response
in the treated individual. However, in elderly patients age-related changes in synthetic activity of the implanted cells
and subsequent alterations in tissue protein content may affect therapeutic outcomes. In this study we investigated
the effect of donor age on proteome composition of tenocyte-derived tendon tissue-engineered constructs.
Results: Liquid chromatography tandem mass spectrometry was used to assess the proteome of tissue-engineered
constructs derived from young and old equine tenocytes. Ageing was associated with altered extracellular matrix
composition, especially accumulation of collagens (type I, III and XIV), and lower cytoskeletal turnover. Proteins involved
in cell responsiveness to mechanical stimuli and cell-extracellular matrix interaction (calponin 1, palladin, caldesmon 1,
cortactin) were affected.
Conclusions: This study demonstrated significant changes in proteome of engineered tendon derived from young
and old tenocytes, indicating the impact of donor age on composition of autologous constructs.
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Background
Ageing is associated with an increasing incidence of ten-
dinopathies and impaired tendon repair following injury
[1–3]. These events are thought to result from age-
related modifications in tendon structure, especially
extracellular matrix (ECM) content, accumulation of
mechanically induced micro-trauma and decreased re-
generative potential of tendon tissue [1, 4–7]. Tendon
adaptability to loading conditions and its healing cap-
acity depend predominantly on the cellular component,
represented by tenocytes and tendon-derived stem cells
(TDSCs) [8–11]. Tenocytes are tendon-specific fibro-
blasts, responsible for production and turnover of the
ECM, while TDSCs are pluripotent cells capable of pro-
liferation and differentiation into adult tenocytes [9, 12].
Current evidence suggests that natural tendon healing
mechanism may be debilitated in chronic tendinopathies
due to diminished proliferative potential of the native
TDSCs [13–15]. TDSCs in tendinopathic tendon are also
more likely to undergo aberrant differentiation into
chondrocyte-like cells rather than tenocytes, further
contributing to tendon degeneration by synthesis of
inadequate ECM components [13, 14, 16, 17].
Tendon engineering combines use of mesenchymal stem
cells (MSCs) or terminally differentiated fibroblasts and
biocompatible scaffolds, providing functional grafts able to
support reconstruction of the damaged tissue [18–21].
Similarly to cell-based therapies, autologous cell sources
are preferred for tendon engineering to prevent host im-
mune response against the implanted graft. Little is known
on the impact of the donor’s age on the histological and
biochemical properties of the tissue-engineered construct
(TEC). Thorough knowledge of the age-related changes in
TEC generated from different cell types is needed to pro-
vide rationale for choosing specific therapeutic option in
older patients as well as selecting allogenic cell donors.
Our recent study evaluating proteomic profiles of chondro-
genic, osteogenic and tenogenic constructs derived from
ageing human MSCs indicated differential expression of
proteins involved in antioxidant protection and energy me-
tabolism in old tendon TEC [22]. ECM matrisomal protein
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content was also affected, with higher numbers of neopep-
tides (indicating increased turnover) for the major ECM
components identified in tenogenic constructs synthesized
from old MSCs. No similar work has yet been undertaken
for TEC generated from tenocytes. Tendon fibroblasts con-
stitute a relevant source of cells used in tendon and liga-
ment engineering [18, 23–25], therefore, investigating
impact of donor age on composition of tenocyte-derived
TEC appears to be of major importance. Several studies in-
vestigating the effects of ageing on the native tendon tissue
reported alterations in ECM composition in older individ-
uals. Increased degradation of type I collagen and de-
creased levels of selected proteoglycans and elastin were
observed in older groups of equine superficial digital flexor
tendon (SDFT) samples and rat Achilles tendon explants
[4, 7, 26, 27]. It is not clear whether these changes are dir-
ectly related to the decreasing ability of tendon cells to
synthesize ECM proteins and/or enhanced release of
matrix metalloproteinases (MMPs) degrading them [5, 6,
27, 28]. Findings from our previous study demonstrated
that tissue engineered fibrin construct created from teno-
cytes derived from skeletally mature tendon shared similar
characteristic with native tendon with regard to prominent
ECM protein. However it is yet to be identified whether
the ECM characteristics will be different in engineered ten-
don created from ageing tenocytes [29].
The horse is a recognised model for studying exercise-
and age-related changes in tendon composition due to
the functional similarity of equine and human energy-
storing tendons and the relatively long lifespan of the
species [30, 31]. Apart from studies analysing tendon
ECM content, referenced above, equine SDFT has been
used to investigate the effect of ageing on mechanical
properties [3], response to fatigue loading [32] and colla-
gen fibre conformation [33]. In the current study we
continue work using equine tenocytes to investigate if
the age of the tenocyte donor can affect the quality of
tissue-engineered tendon contructs.
Methods
The aim of this study was to perform global proteomic
profiling of TEC, derived from equine tenocytes from
young and old donors. We hypothesized that tenocyte
ageing affects proteome of tendon TEC, and that charac-
teristics of these changes would be similar to age-related
processes observed in native tendon. Label-free relative
quantification was employed to explore the impact of
cell age on the abundance of intra- and extracellular
proteins in engineered tendon.
Sample collection
Equine tendons were harvested from the mid region of
grossly normal superficial digital flexor tendons (SDFTs)
from left forelimb of each horse, a single tendon per
donor. Samples were collected as a by-product of the
agricultural industry. Specifically, the Animal (Scientific
Procedures) Act 1986, Schedule 2, does not define
collection from these sources as scientific procedures.
Ethical permission for tissue collection was obtained
from the University of Liverpool Institute of Veterinary
Sciences Research Ethics Committee (VREC352). Seven
young donors (average age ± standard deviation; 4.4 ±
1.7 years) and six old donors (18 ± 2.4) were made into
engineered tendon constucts as described below. The
age of young horses was selected to ensure full skeletal
maturity, whilst the old group included horses of great-
est age obtainable with no abnormalities following gross
tendon examination. Samples were acquired from breeds
other than Thoroughbred racehorses due to high preva-
lence of pathology in tendons from such horses.
Cell culture and tissue engineered construct formation
All chemicals are supplied by Sigma unless stated other-
wise. All methods pertaining to tissue-engineered tendon
have been previously described [22].
Equine tenocytes were isolated from the tendons on
the day of collection and grown to passage 3 as
described previously [15]. Briefly tendon without the
paratendon or tendon sheath, was dissected and digested
for 16 h at 37 °C in 1 mg/ml collagenase II. The cell sus-
pension was strained and pelleted using centrifugation at
1932 G for 10 min. The cells were resuspended in
complete Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% foetal calf serum, penicillin
(100 U/ml), streptomycin (100 mg/ml), and amphoteri-
cin B (2 mg/ml). Cells were seeded at 2.8 × 104 cells/cm2
for construct set-up as previously described [34]. Briefly,
each well of a six-well plate was coated with ~1.5 ml Syl-
gard (type 184 Silicone elastomer, WPI, Hertfordshire,
UK) and pinned with silk sutures to create fixed anchor
points. For creation of three technical fibrin constructs,
1.2 ml of 1.5 × 106 cells/ml were suspended into 250 μl
of 20 mg/ml fibrinogen and 25 μl of 200 U/ml thrombin
(both Sigma-Aldrich, Dorset, UK) added. A volume of
480 μl of the mixture was immediately deposited in each
well and vigorously shaken to ensure an even covering
of the fibrin gel. Each cell- embedded fibrin gel was cul-
tured in 2 ml phenol-red free DMEM supplemented
with 100 U/ml penicillin/streptomycin, 10% FBS (Gibco,
Paisley, UK), 500 ng/ml amphotericin, 2 mM L-
glutamine (both life technologies, Paisley, UK) 200 μM
l-ascorbic acid 2-phosphate (Sigma-Aldrich, Dorset,
UK), non-essential amino acid (Sigma-Aldrich, Dorset,
UK) at 10 μl/ml concentration, 0.02μg/ml human re-
combinant TGFβ-3 (Preprotech, London, UK) and apro-
tinin (Sigma-Aldrich, Dorset, UK) at 10 μl/ml.
Engineered tendon constructs were incubated at 37 °C
with 5% oxygen and harvested at 28 days.
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Protein extraction and sample preparation
Proteins were extracted from the constructs using 0.1%
RapiGest™ [35]. Protein extracts were normalized following
protein assay using the Bradford assay with Coomassie
Plus™ protein assay reagent (Thermo Scientific, Rockford,
IL) read at 660 nm. In-solution trypsin digestion was
undertaken on all samples as described previously [7]. One
sample from each group was excluded from further analysis
due to poor protein extraction and the final number of bio-
logical replicates used in the study was 6 in young and 5 in
old tenocyte group.
Mass spectrometry and label-free quantification
Liquid chromatography tandem mass spectrometry
(LCMS/ MS) was performed using a Ultimate 3000 Nano
system (Dionex/Thermo Fisher Scientific) online The
QExactive (Thermo-Scientific, Waltham, USA) as described
previously [36].
For label-free quantification the Thermo raw files of the
acquired spectra from in-solution tryptic digests were ana-
lysed by the ProgenesisQI™ software (Waters, Manchester,
UK) [37]. Briefly, the top five feature spectra were
exported from Progenesis-QI™ and utilized for peptide
identification in PEAKS® 7 PTM (Bioinformatics Solutions
Inc., Ontario, Canada) using Unihorse database. Search
parameters used were: 10 ppm peptide mass tolerance
and 0.01 Da fragment mass tolerance; one missed cleavage
allowed; fixed modification, carbamidomethylation; and
variable modifications, oxidation of methionine, and
hydroxylation; 3 variable PTMs per peptide.
Proteins were identified with a false discovery rate
(FDR) of 1% and a minimum of two unique peptides
per protein. The resulting peptide-spectrum matches
were imported into ProgenesisQI™ for label-free
relative quantification. Differentially expressed (DE)
proteins were defined with p < 0.05 and ±2-fold
regulation.
The proteomics data were deposited to the ProteomeX-
change Consortium [38] via the PRIDE partner repository
with the dataset identifier PXD005322.
Classification and functional network analysis of
proteomics data
For structural and functional classification of identified
proteins in both young and old TEC Ingenuity Pathway
Analysis (IPA) [39] and Matrisome Project [40] were
used. Networks functional analyses and gene ontology
(GO) annotations of DE proteins were obtained from
IPA and the Search Tool for Retrieval of Interacting
Genes/Proteins (STRING) version 10.0 [41].
Neopeptide identification
Neoeptides derived from extracellular matrix proteins
were identified. The top five feature spectra previously
exported from ProgenesisQI™ for protein identification
were imported into an in-house Mascot server (Version
2.5.1) (Matrix Science, London, UK) and a ‘semi-tryptic’
peptide search carried out using the Unihorse database
with results reimported into ProgenesisQI™. Search pa-
rameters used were: 10 ppm peptide mass tolerance and
0.01 Da fragment mass tolerance; one missed cleavage
allowed; fixed modification, carbamidomethylation; and
variable modifications, methionine, proline and lysine
oxidation with FDR set to 1%.
The ProgenesisQI™ peptide measurements, together
with the Unihorse FASTA file, were imported into a
neopeptide Java application [42]. The application uses
the FASTA protein database to identify the position of
the peptide within the protein and together with assess-
ment of the amino acids preceding and following the se-
quence, assigns peptides as either tryptic or as semi-
tryptic/none-tryptic neopeptides.
The application normalizes neopeptide abundance
through reducing the significance of protein variations
across samples by summing the abundance of all tryptic
peptides identified within the protein and subsequently
calculating the ratio of semi-tryptic to tryptic peptide
abundances for this protein. The application applied a t-test
between young and old TEC groups with p < 0.05
considered significant. Neopeptide fold changes between
the two groups were also calculated.
Immunohistochemistry and biochemical analysis
Immunohistochemistry and biochemical analysis were
used as validation techniques for the most DE proteins
identified by LC-MS/MS. Tendon constructs were fixed
in 4% paraformaldehyde for 48 h, longitudinally embedded
in paraffin and cut into 4 μm thick sections on poly-L-
lysine-coated slide. After endogenous peroxidase blocking
(3%w/v H2O2), sections were pre-incubated in blocking
solution (10% goat serum) for 1 h at room temperature
and incubated overnight at 4 °C at 1/100 dilution with cal-
ponin antibody (ab46794, Abcam, UK). Sections were
washed in phosphate buffered saline (PBS) three times be-
fore being incubated in Ztyochem Plus HRP Polymer anti-
rabbit (ZUC032, Source Bioscience, UK) for 1 h at room
temperature. After incubation, the sections were washed
for three times for 5 min in TBS and incubated with
appropriate of secondary antibody for 1 h at room
temperature. Following washes in PBS immunostaining was
detected with the chromogenic substrate DAB (SigmaFast
3,3-diaminobenzidine, Sigma, UK) and sections counter-
stained with Mayer’s Haemalum for 1 min and washed in
tap water. Control experiments were carried out with omis-
sion of the primary antibody and substitution with non-
immune rabbit IgG (Abcam). No staining was observed in
the control experiments. Immunostained sections were
visualized using Nikon eclipse 80i microscope. Intensity of
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stain was measured using Adobe Photoshop CC image pro-
cessing program. Five biological replicates were analysed in
each group.
Collagen content of tendon constructs (n = 7 in
young and n = 6 in old group) were determined by
hydroxyproline assay using previously described
protocol [43].
Statistical analysis
Statistical analysis performed for proteomic label-free
dataset by ProgenesisQI™. Datasets for hydroxyproline
and semi-quantitative analysis of immunohistochemistry
results were tested for normality using Kolmogorov-
Smirnov test (Graphpad Software, version 7, USA). All
datasets were normally distributed and analysed using t-
test. The significance level was at p < 0.05.
Results
Protein identification and ontology
Total number of 6388 and 6492 peptides assigned to 701
and 710 proteins was identified in young and old tenocyte
derived TEC by liquid chromatography tandem mass spec-
trometry (LCMS/MS). 595 proteins were common between
young and old tenocyte TEC (Fig. 1a). Identified protein
with ≥2 unique peptides, > 1% false discovery rate (FDR)
and -10lgp >20 were considered as significant.
The dataset was transformed to a non-redundant gene
identifier list of the respective human homologues, input
into Ingenuity Pathway Analysis (IPA) and mapped for
protein subcellular location. Proteins ascribed to the
extracellular space were subjected to further
categorization in Matrisome Project [40]. The un-
defined annotations where classified using UNIPROT.
Categorized identified proteins in both young and old
Fig. 1 Number of proteins identified with PEAKS in engineered tendon-derived from young and old tenocytes. a Total number of proteins
identified in respective age groups and common for both TEC types. Classification of all identified proteins was performed based on IPA and
Matrisome Project and presented separately for young (n = 7) (b) and old (n = 6) (c) tenocyte TEC. The bar charts exhibit sublocations of proteins
ascribed to extracellular matrix (ECM)
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constructs proteins are presented in Fig. 1b, c and
Additional file 1.
Label-free relative quantification
To investigate the effect of cell ageing on TEC proteome
composition, label-free quantification was undertaken
on engineered tendon derived from young and old teno-
cytes using ProgenesisQI™. Proteins with a greater than
2-fold change in expression and p < 0.05 were considered
differentially expressed (DE). Among 48 DE proteins 41
demonstrated higher abundance and 7 lower abundance
in TEC from older donors. Proteins with the highest dif-
ferential abundance in each age group are characterized
in Table 1.
Proteins DE between TEC derived from young and old
tenocytes were scanned for functional networks and
pathway analysis using IPA and the Search Tool for
Retrieval of Interacting Genes/Proteins (STRING)
[41]. One significant (IPA score > 40) network related to
‘connective tissue disorders’ was identified for proteins
more abundant in old tenocyte TEC (Fig. 2). The most
significant STRING GO annotations (FDR < 0.001) for
proteins DE in old TEC were: ‘collagen catabolic pro-
cesses’ and ‘extracellular matrix constituent’. STRING
interaction map for proteins DE between old and
young tenocyte TEC is shown in Fig. 3. Both IPA and
STRING analyses of protein-protein interactions
pointed to enhanced ECM turnover in old tenocyte
TEC. Additionally, IPA identified transforming growth
factor beta 1 (TGF-β1) as an upstream regulator of
ECM metabolism (Additional file 2).
Top proteins enriched in the old TEC included cyto-
skeleton organization proteins (calponin 1, palladin), col-
lagens (COL3A1, COL4A2, COL12A1) and transforming
growth factor beta-induced protein (TGFBI) (Fig. 3,
Table 1). STRING analysis determined the main GO cel-
lular component for this group as ‘focal adhesion’ (FDR
< 0.001).The proteins with higher abundance in young
TEC, STRING revealed two subgroups based on
protein-protein interactions: integrins (ITGB3, ITGA5)
and mitochondrial respiratory chain enzymes (ATP syn-
thase, cytchrome b-c1) (Fig. 3, Table 1).
Immunohistochemistry and collagen content
measurement
TEC derived from older tenocytes demonstrated increased
stain intensity of calponin protein (Fig. 4a and b). Semi-
quantitative analysis of calponin in young and old TEC re-
sulted in significantly higher intensity of stain in older
tenocyte derived TEC (p = 0.04) (Fig. 4c).
Collagen content was significantly (p ≤ 0.001) higher in
older tenocyte-derived TEC comparing to young (mean
± standard deviation: 1,66 ± 0,8 and 0,31 ± 0,18, respect-
ively) (Fig. 4d).
Identification of ECM fragment patterns in engineered
tendon
Neopeptides were identified in all samples (data not
shown). There were significantly more neopeptides in
engineered tendon derived from old tenocytes (p < 0.05).
Neopeptides were identified for collagen XIIα1, collagen
1α1 and (Table 2).
Table 1 Table of proteins showing the highest increase in abundance in young (n = 7) and old (n = 6) tenocyte-derived constructs,
according to fold change
Highest mean
condition
Accession
(human)
Protein description Function Peptide
count
Fold
change
ANOVA
(p value)
TEC derived from
old cells
O94875 Sorbin and SH3 domain containing protein 2 Actin filament organization 10 5,1 0,02
V9HWA5 Calponin 1 Actin binding, calmodulin binding 4 3,6 0,02
P02461 Collagen type III alpha 1 ECM Collagen 38 3,5 0,01
O43294 Transforming growth factor beta induced protein ECM Glycoprotein 3 3,2 0,04
Q05707 Collagen type XIV alpha 1 ECM Collagen 3 3,0 0,02
P08123 Collagen type I alpha 2 ECM Collagen 48 3,0 0,00
Q8WX93 Palladin, cytoskeletal associated protein Enzyme 20 3,0 0,02
TEC derived from
young cells
Q99623 Prohibitin 2 Transcription regulator 2 3,9 0,05
P05106 Integrin beta 3 Transmembrane receptor 2 2,8 0,01
P11166 Solute carrier family 2 member 1 Transporter 3 2,2 0,02
P07919 Cytochrome b-c1 complex subunit 6 Enzyme 2 2,1 0,05
P07093 Serpin family E member 2 ECM Regulator 3 2,1 0,04
P08648 Integrin alpha 5 Transmembrane receptor 2 2,1 0,02
P30049 ATP synthase subunit delta, mitochondrial Enzyme 5 2,0 0,04
Only proteins with ≥2 unique peptides and p < 0.05 were presented. Abundant proteins in each group are also highlighted in Additional file 1
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Discussion
This study describes the results of a comprehensive
proteomic analysis of tendon TEC created utilising teno-
cytes from donors of different ages. The results support
the hypothesis, that TEC proteome is dependent upon
the age of the cells used for their creation. The most
affected structural protein group was ECM, similarly to
previous reports in ageing native tendon [7]. General
limitation of this study was our lack of ability to esti-
mate population doubling time once tenocytes were
cultured in the construct setup. A different cell num-
ber within analysed constructs could affect protein
content partitioning and subsequent results of proteomic
analysis. However, the fact that only selected groups
of proteins, intra- and extracellular, showed higher
abundance in old tenocyte derived constructs sup-
ports the hypothesis that those changes could be
attributed to ageing rather than size of cell population
in the construct.
ECM composition depends on age of tenocytes used for
tissue engineering
Although the total number of proteins allocated to
extracellular space did not differ significantly between
the age groups, there was increase in number (Fig. 1b, c)
and abundance (Table 1) of ECM collagens in older
TEC. Increase in total collagen content was confirmed
using a hydroxyproline assay. This novel finding is
contradictory to other reports indicating that collagen
synthesis remains unchanged in ageing native tendon
and tenocyte culture [7, 26–28]. However, aberrations in
collagen turnover leading to the accumulation of its par-
tially degraded forms have been previously suggested to
affect mechanical properties of ECM and contribute to
the development of tendinopathies [26, 28]. In this study
we observed significant increase in the number of neo-
peptides for collagenous proteins identified in old teno-
cyte TEC (Table 2). This was previously reported by our
group in MSC derived engineered tendon [22] and
Fig. 2 IPA top scoring network for proteins differentially abundant in TEC derived from young and old tenocytes. Proteins with higher abundance in
old are displayed in red; with higher abundance in young – in green; with no difference in abundance between young and old – in white. Colour
intensity is related to the increasing fold change in protein abundance between young and old constructs
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suggests increased collagen turnover in TEC generated
from older cells. Collagen metabolism depends on ten-
don fibroblasts, and their altered activity with age may
lead to an accumulation of collagen breakdown prod-
ucts. The principle ontology terms for proteins DE in
old tenocyte TEC were related to collagen catabolism
and disorders of connective tissue. The most abundant
collagen subunit identified in this age group was α2
chain of type III collagen (COL3A2). Increased propor-
tions of type III collagen has been associated with tendi-
nopathies and tendon injuries [44, 45] and tenocytes
isolated from ruptured tendon were described to pro-
duce greater quantities of collagen III in an in vitro
wound healing model [46]. Higher total collagen content
in older TEC may be rather attributed to accumulation
of degraded/abnormal collagen forms and impaired
ECM-organising function of ageing tenocytes than in-
creased fibrillogenesis.
One limitation of this study was that the engineered
tendon was not subjected to mechanical testing;
therefore the direct effect of cell ageing on the func-
tion of the created constructs could not have been
evaluated. Based on literature, the age-related changes
detected in TEC proteome are typically associated
with declined tendon function and increased potential
of injury [26, 44, 45, 47]. However, it would be interest-
ing for the future studies to compare protein compos-
ition of the engineered tendon to its mechanical
Fig. 3 STRING interaction map of proteins differentially abundant between TEC from old (a) and young (b) tenocytes. a Two clusters of proteins
are evident: ECM building collagens and intracellular structural protein involved in cytoskeleton formation. These two groups were also represented in
proteins DE in older MSC constructs. Connections between the clusters signalize mechanical interaction of the cell and ECM, described by the GO
annotation ‘focal adhesion’. The role of TGFBI in cell-collagen interaction is marked by multiple connections with different collagen subtypes. b Identified
interactions involve integrins and respiratory chain enzyme subunits
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properties like stiffness, ultimate tensile strength and
failure strain.
TGFB1 regulates age-related changes in collagen
expression
Transforming growth factor beta-1 (TGF-β1) was identified
as potential upstream regulator of observed protein expres-
sion changes in old tenocyte derived TEC, most likely in re-
lation to increased collagen-related proteins abundance.
Although TGF-β is a well-established stimulator of collagen
synthesis in response to mechanical loading in tendon [10,
48], its expression in tenocytes appears unaffected by age
[6]. The cited study, however, utilized a rat model, which im-
plicates significantly smaller age difference between exam-
ined groups comparing to human and equine studies [3, 4,
7, 22, 49]. In our previous studies TGF-β1 was proposed as
the upstream regulator of age-related changes in cultured
human MSCs [49] and MSC derived engineered tendon
[22]. One of the top DE proteins in older TEC was trans-
forming growth factor beta induced protein (TGFβI) consid-
ered to be regulatory for cell adhesion and cell-collagen
interaction (Fig. 2). Given the strict relation between TGF-
Fig. 4 Immunohistochemistry and collagen content measurement. Immunostainning of calponin on young (n = 7) (a) and old (n = 6) (b) tendon
constructs showed a marked staining in old construct. Significantly higher (* p< 0.05) intensity of calponin staining (c) and higher collagen content (d) was
identified in old tendon constructs
Table 2 Differential collagen neoepitope abundances between tendon tissue-engineered constructs derived from young and old
donors
Protein Accession
Number
Neopeptide Sequence Previous
Amino Acid
Following
Amino Acid
Abundance Higher in
Young or Old
Fold
Change
p value
Collagen type I
alpha 1 chain
F7D939 PQGPAGPAGPIGPVGAR A G Old 0.7 0.008
Collagen type I
alpha 2 chain
F6RTH9 GEAGAAGPAGPAGPRG R S Old 0.6 0.045
AGPVGAVGAPGPHGPVGPTGK N H Old 2.0 0.001
NGLQGLPGLAGQHGDQGAPGSVGPAGPR H G Old 2.7 0.018
Collagen type XII
alpha 1 chain
F6QD89 AIYPDESESDDLIGSERTPR T L Old 5.4 0.001
LEQLIPDTPYSVNIVAL R Y Old 11.9 0.002
LVQYSR S D Young 3.1 0.021
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β1 activity and collagen synthesis, this finding appears to be
in line with age-related changes in ECM collagen content
described here, including the potential role of TGF-β1 in de-
velopment of degenerative changes in tendon [48, 50].
Cytoskeletal turnover is decreased in ageing tenocytes
The cytoskeleton has an important role in the mechanore-
sponsiveness of load-bearing tissues by mediating ECM
strain to the cell nucleus and eliciting appropriate metabolic
reaction [11]. Interaction between ECM and cytoskeleton
occurs through focal adhesions and the intramembrane
protein clusters that are also responsible for the mainten-
ance of cell shape, and its ability to migrate. In this study,
the most DE protein (increased in old cell based TEC) was
the actin microtubule linking molecule, calponin 1 (Table 1).
Calponins are a group of proteins that regulate interactions
between F-actin, tropomyosin and calmodulin. They affect
contractility of smooth muscle cells and participate in cyto-
skeleton organization in non-muscle cells [51–53]. Expres-
sion of calponins is regulated by mechanical tension
exerted through extracellular environment and was demon-
strated to increase in the cells cultured on stiff matrix [53,
54]. High abundance of calponin 1 in old tenocyte TEC
may be related to changes in ECM content that affect
mechanical properties of the engineered tissue and increase
mechanical strain detected by the cells. Apart from calpo-
nin 1, other actin-binding molecules such caldesmon 1,
cortactin and palladin were also identified. Transgelin, cyto-
skeletal protein previously referred to as cellular biomarker
of ageing [55], demonstrated less than two-fold difference
in abundance between young and old TEC. The main func-
tional annotations for this group of proteins were ‘focal ad-
hesion’ (STRING) and ‘cell movement’ (IPA, Additional
file 2) which points to increased content of cytoskeletal
components in older TEC. Increase in the content of inter-
mediate filaments and cytoskeleton-associated proteins was
observed in ageing tendon fibroblasts [7, 27, 51, 56, 57],
MSC/TDSCs [13, 55] and MSC-based engineered tendon
[22]. Accumulation of actin-related molecules was accom-
panied with disrupted cytoskeletal organization and redis-
tribution of focal adhesions within the plasma membrane
[13, 55–57]. These alterations in intracellular structure were
considered to lead to the decrease in cell proliferation and
their migration potential observed in vitro in tendon
wound-healing models [27, 57] and MSC/TDSC cultures
[13, 55, 58]. Similar changes in cytoskeletal components ob-
served in our study may result in impaired ability of TEC
generated from older cells to adapt to changing mechanical
conditions and repair potential injuries. Proteins DE in
young tenocyte-derived TEC also included molecules in-
volved in the cell-ECM interaction, integrin beta-3 and
alpha-5. These integrins are mainly receptors for glycopro-
teins, fibronectin and laminin, and not collagens that were
significantly enriched in older TEC.
Conclusions
This study evaluated for the first time proteomic profile of
TEC synthesized from in vivo aged tenocytes. The results
confirmed age-related changes previously observed in fibro-
blasts and MSCs; alterations in turnover of ECM collagens
and cytoskeletal proteins. However, tenocyte TEC demon-
strated ageing profile closer to native tissue than MSC de-
rived engineered tendon, with the most characteristic
change being the accumulation of collagenous protein and
their breakdown products which may have detrimental con-
sequence. Alterations in protein content of tenocyte TEC
identified in this study may affect their function as tendon
grafts. Our results contribute to the discussion on the effi-
ciency of autologous cell therapies in elderly patients.
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